Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
8.82
+0.19 (2.20%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases.
The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022.
The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Alumis Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Jun 28, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 109 |
| CEO | Martin Babler |
Contact Details
Address: 280 East Grand Avenue South San Francisco, California 94080 United States | |
| Phone | 650 231 6625 |
| Website | alumis.com |
Stock Details
| Ticker Symbol | ALMS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001847367 |
| ISIN Number | US0223071020 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Martin Babler Ph.D. | President, Chief Executive Officer and Chairman |
| Dr. David M. Goldstein Ph.D. | Chief Scientific Officer |
| Roy C. Hardiman J.D. | Chief Business Officer |
| John R. Schroer C.F.A. | Chief Financial Officer |
| Sara Klein | Chief Legal Officer and Corporate Secretary |
| Derrick Richardson | Senior Vice President of People and Culture |
| Claire Langrish Ph.D. | Senior Vice President and Head of Immunology and Translational Science |
| Philip Nunn Ph.D. | Senior Vice President of Pharmacology and Project Team Leader |
| Dr. Jorn Drappa M.D., Ph.D. | Chief Medical Officer |
| Mark Bradley | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 25, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Aug 27, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Aug 13, 2024 | 8-K | Current Report |
| Jul 24, 2024 | D | Notice of Exempt Offering of Securities |
| Jul 18, 2024 | 8-K | Current Report |
| Jul 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jul 5, 2024 | SC 13D | General statement of acquisition of beneficial ownership |